{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T13:02:18Z","timestamp":1784811738369,"version":"3.55.0"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,8,19]],"date-time":"2020-08-19T00:00:00Z","timestamp":1597795200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1144791"],"award-info":[{"award-number":["1144791"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Nucleic Acids"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.omtn.2020.08.019","type":"journal-article","created":{"date-parts":[[2020,8,21]],"date-time":"2020-08-21T11:23:41Z","timestamp":1598009021000},"page":"263-272","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Morpholino Oligomer-Induced Dystrophin Isoforms to Map the Functional Domains in the Dystrophin Protein"],"prefix":"10.1016","volume":"22","author":[{"given":"Dunhui","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abbie M.","family":"Adams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell D.","family":"Johnsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Fletcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9400-893X","authenticated-orcid":false,"given":"Steve D.","family":"Wilton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtn.2020.08.019_bib1","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S1474-4422(18)30024-3","article-title":"Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management","volume":"17","author":"Birnkrant","year":"2018","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.omtn.2020.08.019_bib2","doi-asserted-by":"crossref","first-page":"90","DOI":"10.33590\/emj\/10311993","article-title":"State of the art advances in Duchenne muscular dystrophy","volume":"2","author":"Van Ruiten","year":"2017","journal-title":"EMJ"},{"key":"10.1016\/j.omtn.2020.08.019_bib3","doi-asserted-by":"crossref","first-page":"12140","DOI":"10.1021\/acsnano.8b05721","article-title":"Dystrophin As a Molecular Shock Absorber","volume":"12","author":"Le","year":"2018","journal-title":"ACS Nano"},{"key":"10.1016\/j.omtn.2020.08.019_bib4","doi-asserted-by":"crossref","first-page":"275","DOI":"10.3390\/brainsci5030275","article-title":"Nonmechanical Roles of Dystrophin and Associated Proteins in Exercise, Neuromuscular Junctions, and Brains","volume":"5","author":"Nichols","year":"2015","journal-title":"Brain Sci."},{"key":"10.1016\/j.omtn.2020.08.019_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pediatrneurol.2006.09.016","article-title":"Pathophysiology of duchenne muscular dystrophy: current hypotheses","volume":"36","author":"Deconinck","year":"2007","journal-title":"Pediatr. Neurol."},{"key":"10.1016\/j.omtn.2020.08.019_bib6","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S1474-4422(03)00585-4","article-title":"Dystrophin and mutations: one gene, several proteins, multiple phenotypes","volume":"2","author":"Muntoni","year":"2003","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.omtn.2020.08.019_bib7","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.tips.2018.09.001","article-title":"Precision medicine through antisense oligonucleotide-mediated exon skipping","volume":"39","author":"Li","year":"2018","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.omtn.2020.08.019_bib8","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/humu.20918","article-title":"Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations","volume":"30","author":"Aartsma-Rus","year":"2009","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.omtn.2020.08.019_bib9","doi-asserted-by":"crossref","first-page":"533","DOI":"10.2147\/DDDT.S97635","article-title":"Eteplirsen in the treatment of Duchenne muscular dystrophy","volume":"11","author":"Lim","year":"2017","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.omtn.2020.08.019_bib10","series-title":"FDA grants accelerated approval to first targeted treatment for rare Duchenne muscular dystrophy mutation","year":"2019"},{"key":"10.1016\/j.omtn.2020.08.019_bib11","series-title":"FDA Approves Targeted Treatment for Rare Duchenne Muscular Dystrophy Mutation","year":"2020"},{"key":"10.1016\/j.omtn.2020.08.019_bib12","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/humu.22758","article-title":"The TREAT-NMD DMD Global Database: analysis of more than 7,000 Duchenne muscular dystrophy mutations","volume":"36","author":"Bladen","year":"2015","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.omtn.2020.08.019_bib13","doi-asserted-by":"crossref","first-page":"e0135189","DOI":"10.1371\/journal.pone.0135189","article-title":"DMD mutations in 576 dystrophinopathy families: a step forward in genotype-phenotype correlations","volume":"10","author":"Juan-Mateu","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1016\/j.omtn.2020.08.019_bib14","first-page":"22","article-title":"Spectrum of small mutations in the dystrophin coding region","volume":"57","author":"Prior","year":"1995","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.omtn.2020.08.019_bib15","doi-asserted-by":"crossref","first-page":"15457","DOI":"10.1074\/jbc.R200031200","article-title":"Dystrophin-glycoprotein complex: post-translational processing and dystroglycan function","volume":"278","author":"Michele","year":"2003","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.omtn.2020.08.019_bib16","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1006\/dbio.1994.1103","article-title":"Myogenic cell lines derived from transgenic mice carrying a thermolabile T antigen: a model system for the derivation of tissue-specific and mutation-specific cell lines","volume":"162","author":"Morgan","year":"1994","journal-title":"Dev. Biol."},{"key":"10.1016\/j.omtn.2020.08.019_bib17","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1093\/hmg\/ddg196","article-title":"Morpholino antisense oligonucleotide induced dystrophin exon 23 skipping in mdx mouse muscle","volume":"12","author":"Gebski","year":"2003","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omtn.2020.08.019_bib18","doi-asserted-by":"crossref","first-page":"e73224","DOI":"10.1371\/journal.pone.0073224","article-title":"Identification of new dystroglycan complexes in skeletal muscle","volume":"8","author":"Johnson","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.omtn.2020.08.019_bib19","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/2044-5040-1-35","article-title":"Dystrophin deficiency exacerbates skeletal muscle pathology in dysferlin-null mice","volume":"1","author":"Han","year":"2011","journal-title":"Skelet. Muscle"},{"key":"10.1016\/j.omtn.2020.08.019_bib20","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1111\/j.1440-1681.2006.04403.x","article-title":"Antisense oligonucleotides: from design to therapeutic application","volume":"33","author":"Chan","year":"2006","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"10.1016\/j.omtn.2020.08.019_bib21","doi-asserted-by":"crossref","first-page":"5660","DOI":"10.1093\/nar\/gkl715","article-title":"Rational design and rapid screening of antisense oligonucleotides for prokaryotic gene modulation","volume":"34","author":"Shao","year":"2006","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2020.08.019_bib22","doi-asserted-by":"crossref","first-page":"6697","DOI":"10.1093\/hmg\/ddu388","article-title":"Phosphorylation within the cysteine-rich region of dystrophin enhances its association with \u03b2-dystroglycan and identifies a potential novel therapeutic target for skeletal muscle wasting","volume":"23","author":"Swiderski","year":"2014","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omtn.2020.08.019_bib23","doi-asserted-by":"crossref","first-page":"e0145620","DOI":"10.1371\/journal.pone.0145620","article-title":"Deletion of dystrophin in-frame exon 5 leads to a severe phenotype: guidance for exon skipping strategies","volume":"11","author":"Toh","year":"2016","journal-title":"PLoS ONE"},{"key":"10.1016\/j.omtn.2020.08.019_bib24","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1083\/jcb.135.3.661","article-title":"A new model for the interaction of dystrophin with F-actin","volume":"135","author":"Rybakova","year":"1996","journal-title":"J.\u00a0Cell Biol."},{"key":"10.1016\/j.omtn.2020.08.019_bib25","doi-asserted-by":"crossref","first-page":"28419","DOI":"10.1074\/jbc.273.43.28419","article-title":"A cluster of basic repeats in the dystrophin rod domain binds F-actin through an electrostatic interaction","volume":"273","author":"Amann","year":"1998","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.omtn.2020.08.019_bib26","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1002\/humu.20976","article-title":"Genotype-phenotype analysis in 2,405 patients with a dystrophinopathy using the UMD-DMD database: a model of nationwide knowledgebase","volume":"30","author":"Tuffery-Giraud","year":"2009","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.omtn.2020.08.019_bib27","doi-asserted-by":"crossref","first-page":"15069","DOI":"10.1073\/pnas.1008818107","article-title":"Missense mutations in dystrophin that trigger muscular dystrophy decrease protein stability and lead to cross-\u03b2 aggregates","volume":"107","author":"Singh","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtn.2020.08.019_bib28","doi-asserted-by":"crossref","first-page":"12414","DOI":"10.1073\/pnas.1508755112","article-title":"Disease-proportional proteasomal degradation of missense dystrophins","volume":"112","author":"Talsness","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtn.2020.08.019_bib29","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1038\/emm.2014.117","article-title":"Degradation of misfolded proteins in neurodegenerative diseases: therapeutic targets and strategies","volume":"47","author":"Ciechanover","year":"2015","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.omtn.2020.08.019_bib30","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.bbamcr.2013.06.031","article-title":"Protein quality control and elimination of protein waste: the role of the ubiquitin-proteasome system","volume":"1843","author":"Amm","year":"2014","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.omtn.2020.08.019_bib31","series-title":"Sarepta Therapeutics Completes Submission of New Drug Application Seeking Approval of Casimersen (SRP-4045) for Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 45","year":"2020"},{"key":"10.1016\/j.omtn.2020.08.019_bib32","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1089\/hum.2018.012","article-title":"Micro-Dystrophin Gene Therapy Goes Systemic in Duchenne Muscular Dystrophy Patients","volume":"29","author":"Duan","year":"2018","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtn.2020.08.019_bib33","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/352536a0","article-title":"The mdx mouse diaphragm reproduces the degenerative changes of Duchenne muscular dystrophy","volume":"352","author":"Stedman","year":"1991","journal-title":"Nature"},{"key":"10.1016\/j.omtn.2020.08.019_bib34","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1002\/jor.22236","article-title":"Dystrophin and utrophin \u201cdouble knockout\u201d dystrophic mice exhibit a spectrum of degenerative musculoskeletal abnormalities","volume":"31","author":"Isaac","year":"2013","journal-title":"J.\u00a0Orthop. Res."},{"key":"10.1016\/j.omtn.2020.08.019_bib35","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1038\/sj.mt.6300245","article-title":"Morpholino oligomer-mediated exon skipping averts the onset of dystrophic pathology in the mdx mouse","volume":"15","author":"Fletcher","year":"2007","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2020.08.019_bib36","series-title":"Peptide conjugated, inosine-substituted antisense oligomer compound and method","author":"Iversen","year":"2014"},{"key":"10.1016\/j.omtn.2020.08.019_bib37","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/jgm.838","article-title":"Dystrophin expression in the mdx mouse after localised and systemic administration of a morpholino antisense oligonucleotide","volume":"8","author":"Fletcher","year":"2006","journal-title":"J.\u00a0Gene Med."},{"key":"10.1016\/j.omtn.2020.08.019_bib38","article-title":"Carleton\u2019s Histological Technique","author":"Carleton","year":"1967"}],"container-title":["Molecular Therapy Nucleic Acids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253120302481?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253120302481?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T12:19:24Z","timestamp":1784809164000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2162253120302481"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":38,"alternative-id":["S2162253120302481"],"URL":"https:\/\/doi.org\/10.1016\/j.omtn.2020.08.019","relation":{},"ISSN":["2162-2531"],"issn-type":[{"value":"2162-2531","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Morpholino Oligomer-Induced Dystrophin Isoforms to Map the Functional Domains in the Dystrophin Protein","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Nucleic Acids","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtn.2020.08.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Author(s).","name":"copyright","label":"Copyright"}]}}